We are pioneering a new therapeutic approach to treat debilitating ear, nose and throat (ENT) diseases that impact the lives of millions of people.
Our first product candidate targets chronic rhinosinusitis (CRS), which affects about 14 million in the U.S.
Aug 05, 2020 Lyra Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Aug 04, 2020 Lyra Therapeutics to Present at the BTIG Virtual Biotechnology Conference
